Evaluation of dexamethasone as a chemoprotectant for CCNU-induced bone marrow suppression in dogs

Veterinary and Comparative Oncology

Volumn 7, Issue 1, 2009, Pages 69-77

  Intile, J L ^a   Rassnick, K M ^a   Bailey, D B ^a   Al Sarraf, R ^b   Chretin, J D ^c   Balkman, C E ^a   Flory, A B ^a,d   Kiselow, M A ^a,e   Wakshlag, J J ^a  

^a Department of Obstetrics Gynecology   (United States)

^b Animal Emergency and Referral Associates   (United States)

^c VCA West Los Angeles Animal Hospital ^*  (United States)

^d ANIMAL MEDICAL CENTER   (United States)

^e Veterinary Medical Specialists   (United States)

Author keywords

CCNU; Corticosteroids; Haematologic toxicity; Lomustine; Neutropenia

Indexed keywords

ALKYLATING AGENT; DEXAMETHASONE; GLUCOCORTICOID; LOMUSTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; BONE MARROW; DOG; DOG DISEASE; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; NEUTROPENIA; SCHOOL; TREATMENT OUTCOME; UNITED STATES;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW; DEXAMETHASONE; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOCORTICOIDS; LOMUSTINE; NEUTROPENIA; NEW YORK; SCHOOLS, VETERINARY; TREATMENT OUTCOME;

CANIS FAMILIARIS; MUS;

EID: 65349113105     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2008.00175.x     Document Type: Article

References (32)

1. Kriegler AB, Bernardo D and Verschoor SM. Protection of murine bone marrow by dexamethasone during cytotoxic chemotherapy. Blood 1994; 83: 65-71.
2. Weiss DJ. Leukocyte disorders and their treatment. In: Kirk's Current Veterinary Therapy XII Small Animal Practice, JD Bonagura and R W Kirk R W, eds., Philadelphia, W.B. Saunders Company, 1995: 452-456.
3. Kurkijan CD and Ozer H. Management of adverse effects of treatment. In: Cancer: Principles and Practice of Oncology, 8th edn., VT DeVita, S Hellman and SA Rosenberg, eds., Philadelphia, Lippincott Williams and Wilkins, 2008: 2617-2633.
4. Ogilvie GK, Obradovich JE, Cooper MF, Walters LM, Salman MD and Boone TC. Use of recombinant canine granulocyte colony-stimulating factor to decrease myelosuppression associated with the administration of mitoxantrone in the dog. Journal of Veterinary Internal Medicine 1992; 6: 44-47.
5. Frimberger AE, Moore AS, Rassnick KM, Cotter SM, O'Sullivan JL and Quesenberry PJ. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma. Journal of Veterinary Internal Medicine 2006; 20: 355-364.
6. Lupu M and Storb R. Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model. Veterinary and Comparative Oncology 2007; 5: 14-30.
7. Rinehart J, Keville L, Neidhart J, Wong L, DiNunno L, Kinney P, Aberle M, Tadlock L and Cloud G. Hematopoietic protection by dexamethasone or granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients treated with carboplatin and ifosfamide. American Journal of Clinical Oncology 2003; 26: 448-458.
8. Leggas M, Kuo KL, Robert F, Cloud G, Deshazo M, Zhang R, Li M, Wang H, Davidson S and Rinehart J. Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: Effect on chemotherapy toxicity and efficacy. Cancer Chemotherapy and Pharmacology 2008. Doi:10.1007/s00280-008-0767-x.
9. Rinehart J, Keville L, Measel J, Spiekerman AM and Burke K. Corticosteroid alteration of carboplatin-induced hematopoietic toxicity in a murine model. Blood 1995; 86: 4493-4499.
10. Joyce RA and Chervenick PA. Corticosteroid effect on granulopoiesis in mice after cyclophosphamide. Journal of Clinical Investigation 1977; 60: 277-283.
11. Moore AS, London CA, Wood CA, Williams LE, Cotter SM, L'Heureux DA and Frimberger AE. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. Journal of Veterinary Internal Medicine 1999; 13: 395-398.
12. Rassnick KM, Moore AS, Williams LE, London CA, Kintzer PP, Engler SJ and Cotter SM. Treatment of canine mast cell tumors with CCNU (lomustine). Journal of Veterinary Internal Medicine 1999; 13: 601-605.
13. Williams LE, Rassnick KM, Power HT, Lana SE, Morrison-Collister KE, Hansen K and Johnson JL. CCNU in the treatment of canine epitheliotropic lymphoma. Journal of Veterinary Internal Medicine 2006; 20: 136-143.
14. Skorupski KA, Clifford CA, Paoloni MC, Lara-Garcia A, Barber L, Kent MS, LeBlanc AK, Sabhlok A, Mauldin EA, Shofer FS, Couto CG and Sorenmo KU. CCNU for the treatment of dogs with histiocytic sarcoma. Journal of Veterinary Internal Medicine 2007; 21: 121-126.
15. Saba CF, Thamm DH and Vail DM. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. Journal of Veterinary Internal Medicine 2007; 21: 127-132.
16. Risbon RE, de Lorimier LP, Skorupski KA, Burgess KE, Bergman PJ, Carreras J, Hahn K, Leblanc A, Turek M, Fred R, Wojcieszyn JW, Drobatz K and Clifford CA. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): A retrospective study of 46 cases (1999-2004). Journal of Veterinary Internal Medicine 2006; 20: 1389-1397.
17. Sauerbrey ML, Mullins MN, Bannink EO, Van Dorp TE, Kaneene JB and Obradovich JE. Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005). Journal of the American Veterinary Medical Association 2007; 230: 1866-1869.
18. Morrison-Collister KE, Rassnick KM, Northrup NC, Kristal O, Chretin JD, Williams LE, Cotter SM and Moore AS. A combination chemotherapy protocol with MOPP and CCNU consolidation (Tufts VELCAP-SC) for the treatment of canine lymphoma. Veterinary and Comparative Oncology 2003; 1: 180-190.
19. Thompson NM, Kristal O, Rassnick KM and Moore AS. CCNU in dogs: hematologic toxicity in 300 patients. Proceedings of the 21st Annual Veterinary Cancer Society Conference 2001: 63.
20. Veterinary Co-operative Oncology Group - Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2004; 2: 195-213.
21. Simon R. Design and analysis of clinical trials. In: Cancer: Principles and Practice of Oncology, 8th edn., V DeVita, S Hellman and S Rosenberg, eds., Philadelphia, Lippincott Williams and Wilkins, 2008: 571-589.
22. Gibbons G, Pokras M and Sedgwick C. Allometric scaling in veterinary medicine. Australian Veterinary Practitioner 1988; 18: 160-164.
23. Willis-Goulet HS, Schmidt BA, Nicklin CF, Marsella R, Kunkle GA and Tebbett IR. Comparison of serum dexamethasone concentrations in cats after oral or transdermal administration using pluronic lecithin organogel (PLO): A pilot study. Veterinary Dermatology 2003; 14: 83-89.
24. Rassnick KM, McEntee MC, Erb HN, Burke BP, Balkman CE, Flory AB, Kiselow MA, Autio K and Gieger TL. Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma. Journal of Veterinary Internal Medicine 2007; 21: 1364-1373.
25. Matus RM. Chemotherapy of lymphoma and leukemia. In: Kirk's Current Veterinary Therapy X Small Animal Practice, JD Bonagura and RW Kirk, eds., Philadelphia, W.B. Saunders Company, 1989: 482-488.
26. Duggan DE, Yeh KC, Matalia N, Ditzler CA and McMahon FG. Bioavailability of oral dexamethasone. Clinical Pharmacology and Therapeutics 1975; 18: 205-209.
27. English J, Chakraborty J, Marks V and Parke A. A radioimmunoassay procedure for dexamethasone: Plasma and urine levels in man. European Journal of Clinical Pharmacology 1975; 9: 239-244.
28. Murakami M, Miyachi Y, Nanno M and Yoshimi T. Radioimmunoassay for dexamethasone and its plasma levels after oral administration in patients with liver disease. Nippon Naibunpi Gakkai Zasshi 1990; 66: 760-769.
29. Martin RD, Genoud M and Hemelrijk CK. Problems of allometric scaling analysis: Examples from mammalian reproductive biology. Journal of Experimental Biology 2005; 208: 1731-1747.
30. Mahmood I. Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Advanced Drug Delivery Reviews 2007; 59: 1177-1192.
31. Rinehart J, Delamater EW, Keville L and Measel J. Corticosteroid modulation of interleukin-1 hematopoietic effects and toxicity in a murine system. Blood 1994; 84: 1457-1463.
32. Bono VH Jr. Review of mechanism of action studies of the nitrosoureas. Cancer Treatment Report 1976; 60: 699-702.